|
|
|
|
|
|
By Megan Thielking
Scott Olson/Getty Images
The ride-sharing giants see huge potential in tapping into their driver networks to shuttle patients to and from doctors’ appointments.
Read More
|
|
By Adam Feuerstein
APStock
Investor expectations are running high for Mirati Therapeutics, whose upcoming trial readout may be an important stock-moving catalyst.
Read More
|
|
By Sharon Begley
Adobe
Customers can have their full genome sequenced for free if they let Nebula share their anonymized DNA and other data with corporate partners.
Read More
|
|
Sponsor content by STAT Plus
In-depth biopharma, business, and policy analysis at your fingertips
Sign up for STAT Plus to receive in-depth analysis of the biotech and pharma industries, exclusive one-on-one interviews with industry pioneers, and inside intelligence from Capitol Hill. Don’t be the last to know. Subscribe today to start reading.
|
|
By Matthew Herper
Juno Therapeutics
Bishop, who led Juno until it was sold to Celgene, will be the third chief executive Grail has had since it was founded in 2015.
Read More
|
|
By Rebecca Robbins
Livongo
Livongo's IPO will test whether it’s possible to overcome obstacles that have blocked the emergence of big, financially successful health tech companies.
Read More
|
|
By Adam Feuerstein
Adobe
In the Phase 2 study, three oral doses of the company's lead drug, called seladelpar, all performed worse than a placebo.
Read More
|
|
